Alexandre Bodmer

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Hervé Bonnefoi, Saskia Litière, Martine Piccart et al. · Annals of Oncology · 2014 · 197 citations · Full text

Breast Oncology, Eortc 10994/Big, Medicine +7

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Solène De Talhouet, Julien Péron, Aurélie Vuilleumier et al. · Scientific Reports · 2020 · 122 citations · Full text

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Hervé Bonnefoi, William Jacot, Mahasti Saghatchian et al. · Annals of Oncology · 2014 · 86 citations · Full text

Breast Oncology, Medicine, Pathology +8

Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor

Kamal Ahmed, Alexey Koval, Jiabin Xu et al. · Cancer Letters · 2019 · 67 citations

First Targeted Therapy, Breast Oncology, Medicine +10